{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:58:47Z","timestamp":1794085127658,"version":"4.8.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.berh.2018.12.001","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T23:40:08Z","timestamp":1548891608000},"page":"331-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Advances in understanding the pathophysiology of spondyloarthritis"],"prefix":"10.1016","volume":"32","author":[{"given":"Rik J.","family":"Lories","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10089","key":"10.1016\/j.berh.2018.12.001_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"9783","key":"10.1016\/j.berh.2018.12.001_bib2","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.berh.2018.12.001_bib5","first-page":"2095","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10136","key":"10.1016\/j.berh.2018.12.001_bib6","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.berh.2018.12.001_bib7","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrendo.2010.190","article-title":"The multiple faces of autoimmune-mediated bone loss","volume":"6","author":"Schett","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.berh.2018.12.001_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbapap.2011.06.020","article-title":"Proteases involved in cartilage matrix degradation in osteoarthritis","volume":"1824","author":"Troeberg","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.berh.2018.12.001_bib10","article-title":"Matrix Metalloproteinases: a challenging paradigm of cancer management","author":"Alaseem","year":"2017","journal-title":"Semin Canc Biol"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI23738","article-title":"Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis","volume":"115","author":"Lories","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.berh.2018.12.001_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.rdc.2012.08.003","article-title":"Pathophysiology of new bone formation and ankylosis in spondyloarthritis","volume":"38","author":"Lories","year":"2012","journal-title":"Rheum Dis Clin N Am"},{"issue":"5","key":"10.1016\/j.berh.2018.12.001_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.berh.2014.10.008","article-title":"Bone formation in axial spondyloarthritis","volume":"28","author":"Lories","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/BOR.0000000000000404","article-title":"Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis","volume":"29","author":"Neerinckx","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.12.001_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-017-0639-7","article-title":"Structural disease progression in axial spondyloarthritis: still a cause for concern?","volume":"19","author":"Neerinckx","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/art.34442","article-title":"Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation","volume":"64","author":"Maksymowych","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/art.40028","article-title":"Discovery of T Cell receptor beta motifs specific to HLA-B27-positive ankylosing spondylitis by deep repertoire sequence analysis","volume":"69","author":"Faham","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2018.12.001_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177080","article-title":"Pathogenic variants screening in seventeen candidate genes on 2p15 for association with ankylosing spondylitis in a Han Chinese population","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of ankylosing spondylitis-insights into pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2018.12.001_bib21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","article-title":"Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study","volume":"76","author":"Carron","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2018.12.001_bib22","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/annrheumdis-2012-202245","article-title":"Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib23","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10136","key":"10.1016\/j.berh.2018.12.001_bib24","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.berh.2018.12.001_bib25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","article-title":"Psoriasis: from pathogenesis to targeted therapies","volume":"54","author":"Conrad","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.berh.2018.12.001_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","article-title":"New treatment options for inflammatory bowel diseases","volume":"53","author":"Verstockt","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2018.12.001_bib29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratacos","year":"1994","journal-title":"Br J Rheumatol"},{"issue":"9244","key":"10.1016\/j.berh.2018.12.001_bib30","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","article-title":"Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms","volume":"356","author":"Van den Bosch","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study","volume":"59","author":"Van den Bosch","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib32","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1084\/jem.20070906","article-title":"Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases","volume":"205","author":"Armaka","year":"2008","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.berh.2018.12.001_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.autrev.2005.10.013","article-title":"The role of cytokine mRNA stability in the pathogenesis of autoimmune disease","volume":"5","author":"Seko","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.berh.2018.12.001_bib36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.33321","article-title":"Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats","volume":"64","author":"Glatigny","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2018.12.001_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014108","article-title":"Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis","volume":"5","author":"Res","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.berh.2018.12.001_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11926-015-0507-2","article-title":"IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear","volume":"17","author":"Venken","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.berh.2018.12.001_bib42","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2018.12.001_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/bs.ai.2015.03.003","article-title":"Activation and function of iNKT and MAIT cells","volume":"127","author":"Chandra","year":"2015","journal-title":"Adv Immunol"},{"issue":"12","key":"10.1016\/j.berh.2018.12.001_bib44","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.12.001_bib45","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib47","doi-asserted-by":"crossref","first-page":"81 e5","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.berh.2018.12.001_bib48","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.40319","article-title":"Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor- and interleukin-17-targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib49","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/s41467-017-01771-2","article-title":"Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis","volume":"8","author":"Al-Mossawi","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.berh.2018.12.001_bib50","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/annrheumdis-2013-204835","article-title":"Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis","volume":"74","author":"Cortes","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl. 2","key":"10.1016\/j.berh.2018.12.001_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/XXII.suppl_2.25","article-title":"The enthesopathy of ankylosing spondylitis","volume":"22","author":"Ball","year":"1983","journal-title":"Br J Rheumatol"},{"issue":"9134","key":"10.1016\/j.berh.2018.12.001_bib52","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","article-title":"Classification of inflammatory arthritis by enthesitis","volume":"352","author":"McGonagle","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.berh.2018.12.001_bib53","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.22758","article-title":"The concept of a \"synovio-entheseal complex\" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2018.12.001_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/art.37829","article-title":"Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?","volume":"65","author":"Baeten","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2018.12.001_bib56","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.berh.2018.12.001_bib57","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23-Dependent gamma\/delta T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2018.12.001_bib58","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","article-title":"Brief report: group 3 innate lymphoid cells in human enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"9982","key":"10.1016\/j.berh.2018.12.001_bib59","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0140-6736(15)60970-9","article-title":"Spondyloarthropathy: interleukin 23 and disease modification","volume":"385","author":"Sherlock","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.berh.2018.12.001_bib60","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2018.12.001_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","article-title":"Hla-B27","volume":"33","author":"Bowness","year":"2015","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib62","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/BOR.0b013e3283393807","article-title":"Interactions between gut inflammation and arthritis\/spondylitis","volume":"22","author":"Jacques","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2018.12.001_bib63","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1136\/annrheumdis-2015-207735","article-title":"Spreading spondyloarthritis: are ILCs cytokine shuttles from base camp gut?","volume":"74","author":"Neerinckx","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.12.001_bib64","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.12.001_bib65","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/annrheumdis-2016-209454","article-title":"A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis","volume":"76","author":"De Wilde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1582-4934.2009.00984.x","article-title":"Evidence for the prevention of enthesitis in HLA-B27\/hbeta(2)m transgenic rats treated with a monoclonal antibody against TNF-alpha","volume":"15","author":"Milia","year":"2011","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.berh.2018.12.001_bib67","first-page":"2","article-title":"Anti-IL-17A, but not anti-TNF, can halt pathological new bone formation in experimental spondyloarthritis","volume":"68","author":"van Tok","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2018.12.001_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"Van Tok","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.berh.2018.12.001_bib69","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/ard.2003.013599","article-title":"Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA\/1 mice: a model of psoriatic arthritis","volume":"63","author":"Lories","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib70","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/art.22372","article-title":"Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis","volume":"56","author":"Lories","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/08916934.2014.976630","article-title":"Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice","volume":"48","author":"Ebihara","year":"2015","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.berh.2018.12.001_bib72","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11914-011-0058-z","article-title":"Osteoporosis: a paradox in ankylosing spondylitis","volume":"9","author":"Carter","year":"2011","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.berh.2018.12.001_bib73","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0070-2153(10)90008-2","article-title":"Vertebrate skeletogenesis","volume":"90","author":"Lefebvre","year":"2010","journal-title":"Curr Top Dev Biol"},{"issue":"3","key":"10.1016\/j.berh.2018.12.001_bib74","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2010.148262","article-title":"Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis","volume":"71","author":"Ruiz-Heiland","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib75","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/BOR.0000000000000254","article-title":"Microtrauma: no longer to be ignored in spondyloarthritis?","volume":"28","author":"Van Mechelen","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2018.12.001_bib76","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/annrheumdis-2017-212404","article-title":"Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures","volume":"77","author":"Stemmler","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.12.001_bib77","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1136\/annrheumdis-2014-205428","article-title":"Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA","volume":"74","author":"Hecht","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib78","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.12.001_bib79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/BOR.0000000000000077","article-title":"The effect of tumor necrosis factor-blockade on new bone formation in ankylosing spondylitis: what is the evidence?","volume":"26","author":"Haroon","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.001_bib80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.001_bib81","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar2135","article-title":"Bone morphogenetic proteins in destructive and remodeling arthritis","volume":"9","author":"Lories","year":"2007","journal-title":"Arthritis Res Ther"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218301013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218301013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:18:19Z","timestamp":1761499099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694218301013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521694218301013"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.12.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in understanding the pathophysiology of spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}